A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
Clinical trial NCT07091019 · RECRUITING
Trial details
- NCT number
- NCT07091019
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-12-17
- Primary completion
- 2033-04-20
- Enrollment
- 1000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.